List of Excipients in Branded Drug BUPROPION HYDROCHLORIDE (XL)

« Back to Dashboard

Generic Drugs Containing BUPROPION HYDROCHLORIDE (XL)

Company	Ingredient	NDC	Excipient
Lannett Company Inc	bupropion hydrochloride	0527-2415	AMMONIA
Lannett Company Inc	bupropion hydrochloride	0527-2415	BUTYL ALCOHOL
Lannett Company Inc	bupropion hydrochloride	0527-2415	ETHYLCELLULOSE

What are the Most Frequently-Used Excipients in BUPROPION HYDROCHLORIDE (XL)?

# Of NDCs	Excipient
17	AMMONIA
17	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE

Bupropion Hydrochloride XL Excipient Strategy and Commercial Opportunities

Last updated: October 27, 2026

Bupropion hydrochloride extended-release, or bupropion XL, is a mature generic market with limited active-molecule exclusivity and meaningful formulation risk. The commercial opportunity is concentrated in robust controlled-release matrices, reliable dissolution performance, 450 mg once-daily products, contract manufacturing, and differentiated dosage forms that remain within FDA bioequivalence requirements. Excipient selection directly affects dose dumping, food effects, metabolite exposure, tablet robustness, and manufacturing cost.

What is the FDA and commercial status of bupropion hydrochloride XL?

Bupropion hydrochloride XL is marketed primarily for major depressive disorder and seasonal affective disorder. Wellbutrin XL was approved under NDA 021515. Generic bupropion hydrochloride extended-release tablets are approved through the ANDA pathway. The XL product is distinct from immediate-release bupropion and sustained-release products such as Wellbutrin SR and Zyban.

Parameter	Bupropion hydrochloride XL
Active ingredient	Bupropion hydrochloride
Common strengths	150 mg and 300 mg
Other commercial strength	450 mg, including Forfivo XL
Dosage form	Once-daily extended-release tablet
Primary indications	Major depressive disorder; seasonal affective disorder
FDA pathway	NDA for branded products; ANDA for generics
Reference product	Wellbutrin XL
Key pharmacokinetic concern	Controlled release of bupropion and active metabolites
Primary formulation risk	Rapid release, alcohol-induced dose dumping, and dissolution variability
Administration restriction	Tablets must be swallowed whole and not crushed, split, or chewed

The 450 mg product is commercially important because it offers a once-daily dose for patients who require a higher total daily dose. Forfivo XL was approved as a 450 mg extended-release product and is not simply a larger version of a 150 mg tablet from a manufacturing or regulatory perspective.

What excipients are used in bupropion XL formulations?

Bupropion XL tablets generally use a matrix or multiparticulate release system with hydrophilic and hydrophobic excipients. The precise composition varies by manufacturer and may be protected by formulation patents, trade secrets, or both.

Typical excipient classes include:

Excipient class	Common examples	Primary function
Hydrophilic matrix former	Hypromellose, also called HPMC	Swelling, gel formation, and diffusion control
Hydrophobic release modifier	Ethylcellulose, glyceryl behenate	Slower water penetration and drug release
Binder	Povidone, hypromellose	Granule and tablet cohesion
Diluent	Microcrystalline cellulose, lactose, mannitol	Dose uniformity and compressibility
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, stearic acid	Ejection and tooling protection
Coating polymer	Hypromellose, ethylcellulose, methacrylate polymers	Protection, appearance, and supplemental release control
Plasticizer	Polyethylene glycol, triacetin	Film flexibility
Colorant or opacifier	Titanium dioxide, iron oxides	Product identification and light protection

The Wellbutrin XL label identifies excipients including ethylcellulose, glyceryl behenate, hypromellose, povidone, and colloidal silicon dioxide in the tablet system. Generic products may use different excipients while maintaining equivalent release and exposure profiles (FDA, 2024a).

Which excipient strategy is most suitable for bupropion XL?

A robust commercial strategy is a hydrophilic-hydrophobic matrix that combines HPMC with a water-resistant polymer or lipid excipient. HPMC provides predictable swelling and gel formation. Ethylcellulose or glyceryl behenate can reduce initial water ingress and moderate release during the early dissolution phase.

A formulation development program should optimize:

1. Polymer viscosity grade.
2. Polymer concentration.
3. Drug-to-polymer ratio.
4. Granulation moisture and endpoint.
5. Compression force and tablet porosity.
6. Lubrication time.
7. Coating weight gain.
8. Dissolution across pH conditions.
9. Mechanical strength after packaging and transport.

High-viscosity HPMC can reduce burst release but may increase tablet size, compression force, and manufacturing cycle time. Low-viscosity HPMC improves processability but may create a higher risk of early release. Ethylcellulose can improve release control but may complicate aqueous processing and increase dependence on coating or granulation uniformity.

Glyceryl behenate is attractive for direct-compression or lipid-matrix approaches because it provides hydrophobic release control and can improve tablet handling. Its performance can vary with particle size, polymorphic form, and mixing conditions. A lipid-rich system also requires careful control of dissolution after storage because changes in wettability may alter release.

How does excipient selection affect dissolution?

Bupropion XL requires a dissolution profile that remains controlled over the intended dosing interval. A formulation that releases too quickly may increase peak concentrations and seizure risk. A formulation that releases too slowly may reduce therapeutic exposure or produce unacceptable metabolite profiles.

Critical dissolution variables include:

• Acid-stage release.
• Buffer-stage release.
• Agitation speed.
• Apparatus type.
• Media volume and pH.
• Tablet orientation.
• Alcohol exposure.
• Storage-related changes in porosity and polymer hydration.

The formulation should be tested against the reference product across multiple time points rather than relying only on a final percentage released. Similarity-factor analysis, discriminatory dissolution methods, and stress testing are central to a defensible ANDA package.

What excipients create the greatest commercial and regulatory risk?

The highest risks come from excipients that create variability rather than from the cost of the excipient itself.

Hypromellose variability

HPMC is sensitive to viscosity grade, substitution pattern, particle size, and hydration behavior. A change in supplier or grade can alter the gel layer and shift the dissolution curve. Dual sourcing requires comparability work.

Lubrication sensitivity

Excessive magnesium stearate or prolonged blending can reduce wetting and slow dissolution. Under-lubrication can create sticking, weight variation, and tablet defects. Lubrication is particularly important for high-dose tablets, where the formulation has limited room for inactive ingredients.

Colloidal silicon dioxide

Colloidal silicon dioxide improves flow but can alter powder packing and tablet porosity. Excess use may increase dusting, electrostatic behavior, or blend segregation.

Povidone and moisture

Povidone improves binding but can increase moisture sensitivity. Water activity can affect compaction, tablet hardness, and release performance. Packaging should be selected based on measured moisture uptake rather than nominal excipient properties.

Coating systems

A functional coating can help control release and reduce surface defects, but it increases process complexity and cost. An overreliance on coating to compensate for an unstable core increases batch-to-batch risk.

What FDA requirements apply to generic bupropion XL?

FDA approval requires pharmaceutical equivalence, bioequivalence, quality manufacturing, and adequate controls for extended release. For bupropion XL, bioequivalence is complicated by the parent drug and active metabolites. Hydroxybupropion and other metabolites contribute to the exposure assessment because bupropion undergoes extensive metabolism.

Generic developers should expect scrutiny of:

• Fasting and fed single-dose studies.
• Parent and metabolite pharmacokinetics.
• Multiple strengths and proportionality.
• In vitro dissolution across relevant media.
• Alcohol dose-dumping performance.
• Tablet integrity and resistance to crushing.
• Stability under long-term and accelerated conditions.
• Manufacturing scale-up.
• Differences in inactive ingredients with potential clinical relevance.

FDA has issued product-specific guidance for bupropion hydrochloride extended-release tablets. The guidance reflects the difficulty of demonstrating equivalence for modified-release products and the historical clinical concerns associated with some bupropion XL generics (FDA, 2024b).

What patent protection covers bupropion XL?

Bupropion XL has limited current composition-of-matter protection. The commercial barriers historically centered on sustained-release formulation patents and related manufacturing claims.

Historical patent	General subject matter	Commercial relevance
US 5,427,798	Sustained-release bupropion formulations	Foundational historical protection; original term has expired
US 6,905,708	Extended-release bupropion formulation technology	Historical formulation protection; original term has expired or reached the end of its adjusted term
Brand-specific formulation and use claims	Release profile, dosage form, and therapeutic use	Relevant to historical Paragraph IV and settlement activity

The Orange Book remains the controlling source for listed patents and exclusivity associated with a specific NDA. Patent listings can differ between branded products and later 505(b)(2) products. A generic sponsor must evaluate current Orange Book listings, patent-use codes, regulatory exclusivity, and litigation history before filing a Paragraph IV certification (FDA, 2024c).

Are Paragraph IV challenges still a major barrier?

For standard bupropion XL strengths, the main patent barriers have largely been overtaken by generic approval and market entry. The principal commercial risk is therefore formulation performance and price competition, not an unexpired active-ingredient patent.

Paragraph IV risk can still arise for:

• New 450 mg presentations.
• Novel sprinkle or orally disintegrating formats.
• Combination products.
• Modified-release technologies with new claims.
• Products approved through the 505(b)(2) pathway.
• New indications supported by method-of-use claims.

A sponsor pursuing a differentiated dosage form should perform a fresh Orange Book and patent-family review rather than rely on the expired estate surrounding Wellbutrin XL.

What formulation patents could still protect a new bupropion product?

A new product may obtain protection for a specific release architecture rather than for bupropion itself. Potential claim categories include:

• Multiparticulate extended-release beads.
• Abuse-deterrent or tamper-resistant matrices.
• Sprinkle formulations compatible with selected foods.
• High-load 450 mg tablets.
• Low-swelling matrices.
• pH-independent release systems.
• Alcohol-resistant release profiles.
• Combination products.
• Manufacturing processes that produce a defined dissolution profile.
• Narrow particle-size distributions or coating structures.

Patent strength depends on claim breadth and the ability to design around the formulation. A broad claim to a conventional HPMC matrix is likely to face validity and obviousness pressure. A narrower claim tied to a measurable release profile, defined excipient ratios, or a distinctive manufacturing process may be commercially useful but easier to design around.

What commercial opportunities exist for bupropion XL excipients?

Can excipient suppliers win share in bupropion XL?

Yes. The strongest opportunity is not a new excipient but a qualified, reproducible supply platform. Generic manufacturers value:

• Multiple approved manufacturing sites.
• Tight viscosity and particle-size specifications.
• Low extractables and controlled microbiological quality.
• Regulatory documentation suitable for ANDA submissions.
• Change-control discipline.
• Technical support for dissolution investigations.
• Reliable supply of HPMC, ethylcellulose, glyceryl behenate, and functional coating systems.

An excipient supplier that can demonstrate reduced dissolution variability across scale-up has a stronger commercial position than one competing only on unit price.

Is there an opportunity for premium excipients?

A premium excipient can command value when it solves a measurable manufacturing problem. Examples include directly compressible lipid matrices, engineered HPMC grades, co-processed fillers, and functional coating dispersions. The value proposition should be linked to lower rejection rates, faster development, reduced coating time, or more consistent dissolution.

Is a 450 mg product commercially attractive?

The 450 mg segment offers a differentiated opportunity because it reduces pill burden and supports once-daily dosing. It also creates higher formulation and manufacturing demands. The active load leaves less room for release-controlling excipients, so tablet size, hardness, content uniformity, and dose-dumping performance become more difficult.

A 450 mg product may be commercially attractive when it provides:

• Reliable once-daily dosing.
• Competitive acquisition cost.
• Strong supply continuity.
• A tablet size acceptable to patients.
• A distinct package or distribution position.
• A formulation with less dissolution variability than existing products.

Which companies are challenging bupropion XL?

The market includes branded and generic manufacturers, contract development and manufacturing organizations, and specialty pharmaceutical companies. The principal competitive categories are:

Competitor category	Commercial strategy
Large generic manufacturers	Scale, low cost, pharmacy distribution
Specialty manufacturers	450 mg products, niche dosage forms, targeted contracting
Brand sponsors	Differentiated labeling, supply reliability, authorized generic arrangements
CDMOs	Formulation development, scale-up, analytical method transfer
Excipient suppliers	Release-control systems and supply qualification

The market is price-sensitive, but shortages, recalls, and manufacturing interruptions can create temporary opportunities for secondary suppliers. Bupropion XL is particularly sensitive to quality events because dissolution performance is central to clinical acceptability.

What litigation, settlements, and regulatory risks affect the market?

Historical litigation around bupropion XL focused on patent validity, infringement, generic entry, and the adequacy of generic release characteristics. Generic products also faced regulatory scrutiny when dissolution behavior or clinical performance differed from the reference product.

A current commercial assessment should prioritize:

• FDA warning letters and recalls.
• ANDA status and tentative approvals.
• Current Orange Book listings.
• Patent litigation involving new dosage forms.
• Product-specific guidance revisions.
• Changes in bioequivalence standards.
• Manufacturing site inspections.
• Supply disruptions involving critical polymers.

The principal generic launch scenario is a conventional ANDA product using a controlled-release matrix and relying on expired or nonblocking brand patents. The higher-value scenario is a differentiated 450 mg or patient-convenience product supported by formulation know-how and potentially new patent claims.

How strong is the bupropion XL patent estate?

The legacy estate is weak as a barrier to conventional generic entry because the main sustained-release patent terms have expired or reached the end of their original commercial life. The remaining strength lies in execution barriers:

• Complex dissolution matching.
• Metabolite bioequivalence.
• Alcohol dose-dumping control.
• Scale-up reproducibility.
• Excipient qualification.
• Manufacturing-site compliance.

For investors and licensors, bupropion XL is better viewed as a formulation and supply-chain opportunity than as a classic patent-protected asset.

Key Takeaways

• Bupropion XL is a mature, genericized market with limited active-ingredient patent protection.
• HPMC combined with ethylcellulose or glyceryl behenate is a practical release-control strategy.
• Excipient variability can materially change dissolution and bioequivalence performance.
• The largest technical risks are dose dumping, food effects, metabolite exposure, and scale-up variability.
• A 450 mg once-daily product offers the clearest dosage-form opportunity.
• Excipient suppliers can compete through reproducibility, technical support, and regulatory documentation.
• Conventional bupropion XL products face price pressure; differentiated delivery systems require stronger formulation and patent positions.
• Current Orange Book listings, FDA product-specific guidance, and litigation records should control any launch or licensing decision.

FAQs

What is the best polymer for bupropion hydrochloride XL?

HPMC is usually the core release-controlling polymer, often combined with ethylcellulose or a lipid excipient to moderate water ingress and reduce early release.

Can bupropion XL be reformulated with fewer excipients?

Yes, but reducing excipient count can increase dependence on the remaining polymer, lubricant, and manufacturing process. A simpler formula is commercially useful only if it maintains dissolution and bioequivalence.

Is bupropion XL suitable for an abuse-deterrent formulation?

It is technically possible, but the commercial case depends on clinical need, development cost, and whether the new formulation can obtain meaningful regulatory or patent differentiation.

What is the main difference between bupropion SR and XL formulation strategy?

Bupropion SR generally uses a twice-daily controlled-release design, while XL requires a release system capable of maintaining exposure over approximately 24 hours with tighter control of early release and food effects.

Which excipient has the greatest impact on bupropion XL dissolution?

The release-controlling polymer system, particularly HPMC viscosity grade and concentration, usually has the greatest direct effect. Lubrication, porosity, moisture, and coating conditions can materially modify that effect.

References

1. U.S. Food and Drug Administration. (2024a). Wellbutrin XL: Prescribing information. Drugs@FDA. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024b). Product-specific guidance for generic drug development: Bupropion hydrochloride extended-release tablets. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
4. U.S. Food and Drug Administration. (2023). Inactive ingredient database. https://www.accessdata.fda.gov
5. U.S. Patent No. 5,427,798. (1995). Sustained-release bupropion formulations. U.S. Patent and Trademark Office.
6. U.S. Patent No. 6,905,708. (2005). Sustained-release bupropion formulations. U.S. Patent and Trademark Office.